Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure


Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.

Full Title of Study: “Use of Near Infrared Spectroscopy in Preterm Infants to Determine Patent Ductus Arteriosus Closure Following Medical Treatment”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2018


  • Device: near infrared spectroscopy
    • Near infrared spectroscopy will be placed on infants both with and without hsPDA

Arms, Groups and Cohorts

  • no PDA
    • These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
  • hsPDA
    • These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography

Clinical Trial Outcome Measures

Primary Measures

  • Change in NIRS readings
    • Time Frame: 3 days

Participating in This Clinical Trial

Inclusion Criteria

  • preterm infants less than 32 weeks gestation Exclusion Criteria:

  • infection, congenital heart disease, syndromic anomalies, and perinatal asphyxia.

Gender Eligibility: All

Minimum Age: 1 Minute

Maximum Age: 1 Week

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Albany Medical College
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kate Tauber, Assistant Professor – Albany Medical College

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.